Pegaptanib sodium
As of the edition of 20 October 2026, Pegaptanib sodium is a small molecule: marketed, first approved in 2004 (US); acts on VEGFA; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2008
- Kind
- Small molecule
- Brand name
- Macugen
- First approved
- 17 December 2004 (US)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Pfizer; 2 holders in all
- Registered trials
- 37, 8 stopped early
- Disease areas
- Eye; Heart and blood vessels; Cancer; Hormones; Inherited and neonatal; Nervous system
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Pegaptanib sodium.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| VEGFA | Vascular endothelial growth factor A, long form | P15692 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 11 | 8 | 0 | 2 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 7 | 5 | 0 | 2 |
| Phase 3 | 8 | 6 | 0 | 1 |
| Phase 4 | 9 | 4 | 0 | 3 |
| All trials | 37 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Eyetech Pharmaceuticals | Earlier holder and Lead sponsor of trials | 2001 to now |
| Pfizer | Applicant and Lead sponsor of trials | 2004 to now |
| Bausch Health | Acquired holder and Lead sponsor of trials | 2010 to now |